Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. September 2025 10:00 ET | Quelle: Medicovestor Inc

Medicovestor, Inc. Wins First Place at the Next Star North America Biomedical Special Competition in Boston, part of the 2025 Entrepreneur Next Star Million Prize Global Challenge

Medicovestor wins First Place at the 2025 Next Star Biomedical Competition in Boston for groundbreaking ADC platforms targeting pancreatic & ovarian cancer
17. Juni 2025 10:00 ET | Quelle: Medicovestor Inc

FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic Cancer

FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.
09. Juni 2025 10:00 ET | Quelle: Medicovestor Inc

Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.
28. Oktober 2024 10:00 ET | Quelle: Medicovestor Inc

Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO

Medicovestor secures 3 USPTO patents, advancing its innovative ADC platform and unique antibodies for enhanced cancer treatment and autoimmune potential.
05. April 2024 10:00 ET | Quelle: Medicovestor Inc

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit

Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.
20. November 2023 10:00 ET | Quelle: Medicovestor Inc

Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms

Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.